Int J Cancer:尿前列腺素E2代谢产物与胰腺癌风险的前瞻性研究

2017-08-31 MedSci MedSci原创

环氧合酶2(COX-2)通路在许多胰腺癌细胞中的表达是上升的,前列腺素E2(PGE2)作为COX-2催化花生四烯酸而产生的中间产物,在多种肿瘤中表达显著增加,且与肿瘤的发展相关。因此,有人认为COX-2上调的致癌作用主要是通过前列腺素E2(PGE2)的生产过剩造成的。来自美国的研究小组通过评估尿PGE2代谢物(PGE-M,体内PGE2生产过剩的一种生物标志物)和胰腺癌风险之间的相关性来验证这一假说

环氧合酶2(COX-2)通路在许多胰腺癌细胞中的表达是上升的,前列腺素E2(PGE2)作为COX-2催化花生四烯酸而产生的中间产物,在多种肿瘤中表达显著增加,且与肿瘤的发展相关。因此,有人认为COX-2上调的致癌作用主要是通过前列腺素E2(PGE2)的生产过剩造成的。

来自美国的研究小组通过评估尿PGE2代谢物(PGE-M,体内PGE2生产过剩的一种生物标志物)和胰腺癌风险之间的相关性来验证这一假说。

这是一项病例对照研究,研究共纳入了722例(239例病例和483例对照)参与者,这些参与者嵌套在两个前瞻性队列研究中,分别为上海妇女健康研究(SWHS)和上海男性健康研究(SMHS)。研究人员在确诊之前的尿液样本中,使用液相色谱/质谱法测量PGE-M的含量。采用条件logistic回归估计比值比(OR)和95%置信区间(95%CI),并对潜在的混杂因素进行了调整。

研究发现,与尿液样本中PGE-M含量最少的组(第一个四分位数)相比,尿PGE-M水平相对较高的参与者患胰腺癌的风险增加,调整后的OR(95% CI)为1.63(0.98-2.73,第二个四分位组),1.55(0.90-2.69,第三个四分位组)和1.94(1.07-3.51,第四个四分位组)(趋势P = 0.054)。剂量效应正相关性在BMI <25 kg/m2的参与者中比超重参与者中更明显(交互P = 0.058)。排除随访和对照组在确诊后的第一年数据,剂量效应的正相关性持续存在(趋势P = 0.037)且互相具有统计学意义(P互动 = 0.017)。

本研究的结果为证明COX-2通路参与了胰腺癌的发生增加了额外的证据,研究人员提示尿PGE-M可作为预测胰腺癌风险的生物标志物。

原始出处:

Cui Y, Shu XO,et al.Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk.Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.31007. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2018-02-26 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-11-28 1771ae4158m

    学习一下很不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-15 虈亣靌

    未来的发展前景广阔

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-02 虈亣靌

    好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛.

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2006398, encodeId=67cf200639836, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Tue Oct 24 22:58:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061665, encodeId=33fb2061665e9, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Feb 26 23:58:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744853, encodeId=15d31e448531c, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Sun May 06 19:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265024, encodeId=e3c9265024b6, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Nov 28 11:00:03 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914449, encodeId=2dff19144491c, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jun 02 00:58:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244387, encodeId=e34324438e4a, content=未来的发展前景广阔, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Sep 15 20:45:22 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239734, encodeId=174f239e341c, content=好文.值得点赞!认真学习了.把经验应用于实践.为患者解除病痛., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Sep 02 13:43:30 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513445, encodeId=a4ff151344593, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569532, encodeId=5b05156953279, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Fri Sep 01 15:58:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239186, encodeId=30aa23918641, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Sep 01 06:32:17 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 txqjm

    谢谢了.学习

    0

相关资讯

Sci Rep:不同类型胰腺癌细胞中KRAS突变的异质性

胰腺导管腺癌(PDAC)是一种破坏性疾病,血液中的循环肿瘤细胞(CTC)被认为是全身肿瘤扩散的手段。PDAC是美国和欧洲癌症相关死亡的第四大原因,发生率几乎等于死亡率,5年生存率<6%。这主要是由于其在转移期经常晚期诊断,具侵袭性,并仅对部分已知化学疗法应答。

Sci Rep:miR-107的缺乏促进了胰腺癌的发展

血浆中肿瘤抑制因子miR-107的减少与肿瘤进展有关,是治疗胰腺癌新型靶点。本研究探讨胰腺癌(PCa)患者肿瘤抑制微小RNA(miRNA)血浆水平的降低,以阐明其作为新生物标志物和治疗靶点的潜力。研究使用基于microRNA阵列的方法通过比较PCa患者和健康志愿者的血浆水平来选择候选者。选择六个下调的miRNA(miR-107,miR-126,miR-451,miR-145,miR-491-5p和

神奇!智能手机自拍竟能筛查胰腺癌

胰腺癌预后不佳,五年生存率仅为9%,部分原因是因为没有指示症状或非侵入性筛查工具在肿瘤传播之前识别肿瘤。现在,华盛顿大学(UW)的研究人员开发了一个可以让人们轻松筛查胰腺癌和其他疾病的应用程序——通过智能手机拍摄个人自拍照。

Gastroenterol:广州医科大学唐道林教授团队发现治疗胰腺癌的新药物和新机制

近日,广州医科大学附属第三医院特聘教授唐道林带领的团队,在胰腺癌的治疗领域取得了突破性进展,他们不仅发现了一种新的胰腺癌药物,还阐明了程序性坏死的新型调控分子机制。 对于缺医少药,且表现极度恶劣的胰腺癌而言,唐教授团队的新发现显得弥足珍贵。相关的研究成果刊登在消化领域顶级期刊《肠胃病学》(胃肠病学研究排名第1的期刊,2016年影响因子为18.392)上

JCO:吉西他滨+厄洛替尼辅助治疗胰腺导管腺癌,患者能否获益?

胰腺导管腺癌是一类预后非常差的恶性肿瘤,缺乏有效的治疗靶点。在晚期胰腺癌中发现,吉西他滨联合厄洛替尼,相比吉西他滨单药显着延长OS。基于此,进行了CONKO-005研究,旨在R0切除术后的胰腺导管腺癌中,探索吉西他滨联合厄洛替尼对比吉西他滨单药,能否给患者带来生存获益。

MOL CELL:诱发胰腺癌生长和扩散的“根源”已确定!

来自耶鲁大学的一项研究发现,胰腺癌细胞利用葡萄糖生存,并且扩散到其他器官。众所周知,胰腺癌是一种非常致命的疾病,胰腺癌患者不仅痛苦不堪,而且可供胰腺癌患者选择的治疗方法也是少之又少。然而,近期,由耶鲁大学领导的研究团队已经确定了一个基因,这种基因对胰腺癌细胞的生长至关重要,这一研究为新疗法确定了新目标。